Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Long-Term Phase III Study of STN1012600 Ophthalmic Solution Alone and in Combination With Timolol Ophthalmic Solution, in Subjects With Open Angle Glaucoma or Ocular Hypertension (Angel-J2 Study)

NCT05503901 is registered in ClinicalTrials.gov with Santen Pharmaceutical Co., Ltd. as lead sponsor.

NCT NCT05503901
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05503901 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Long-Term Phase III Study of STN1012600 Ophthalmic Solution Alone and in Combination With Timolol Ophthalmic Solution, in Subjects With Open Angle Glaucoma or Ocular Hypertension (Angel-J2 Study)
Lead sponsor
Santen Pharmaceutical Co., Ltd.
Phase
Phase 3
Overall status
Completed
Start date
August 8, 2022
Completion date
January 30, 2024
Enrollment
131 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

open angle glaucoma, ocular hypertension